CervoMed Inc

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CervoMed, Inc. is a clinical stage biotechnology company. It engages in the business of advancing CNS focused therapeutics to benefit patients with a range of degenerative diseases of the brain. The company is currently developing neflamapimod, an investigational orally administered small molecule brain penetrant that inhibits p38MAP kinase alpha. The company was founded in1995 and is headquartered in Boston, MA.

BOSTON, Feb. 21, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for degenerative diseases of the brain, today announced that Company's Management will present at the BIO CEO and Investor Conference on February 26, 2024, being held in New York, NY and participate in one-on-one investor meetings.

CervoMed to Participate in the BIO CEO and Investor Conference

-Integrated summary of all previously published Phase 2a clinical results, together with the first peer reviewed publication of EEG and MRI results, substantially derisk the ongoing RewinD-LB Phase 2b trial of neflamapimod in dementia with Lewy bodies -

CervoMed Publishes Positive Results from AscenD-LB Phase 2a Trial in Peer-Reviewed Journal that Supports the Therapeutic Potential of Neflamapimod in Dementia with Lewy Bodies

Dr. Boger is the founder, and retired CEO and Board Chair, of Vertex Pharmaceuticals CervoMed on track to complete enrollment in 1H 2024 in its RewinD-LB Phase 2b clinical trial evaluating neflamapimod in patients with dementia with Lewy bodies; topline data expected in 2H 2024 BOSTON, Feb. 07, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical-stage company developing treatments for degenerative diseases of the brain, today announced the appointment of Joshua Boger, Ph.D., to its Board of Directors (Board) and as Chair of the Board.

CervoMed Announces Appointment of Industry Leader Joshua Boger, Ph.D., as Chair of the Board

BOSTON, Feb. 05, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for degenerative diseases of the brain, today announced that Company's Management will provide a corporate update at the Emerging Growth Conference 67, to be held virtually from February 7-8, 2024.

CervoMed to Participate in the Emerging Growth Conference 67

BOSTON, Jan. 05, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for degenerative diseases of the brain, today announced that Company's Management will provide a corporate update at the Emerging Growth Conference 66, to be held virtually from January 10-11, 2024.

CervoMed to Participate in the Emerging Growth Conference 66

Dosed first patient in Phase 2b RewinD-LB study evaluating neflamapimod in patients with dementia with Lewy bodies (DLB) Multiple peer-reviewed journal publications and a conference presentation inform on the potential of neflamapimod in DLB and probability of success in optimized RewinD-LB study Completed reverse merger; company now publicly traded on Nasdaq ("CRVO") CervoMed has cash runway through the end of 2024, by which time the topline primary efficacy results from the Phase 2b RewinD-LB study are expected to be available BOSTON , Nov. 13, 2023 /PRNewswire/ -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for degenerative diseases of the brain, today announced financial results for the third quarter ended September 30, 2023, and provided recent business highlights. "This has been an active and exciting quarter as we completed our merger and launch of CervoMed, while also enrolling the first patient in our RewinD-LB Phase 2b study of neflamapimod for dementia with Lewy bodies (DLB)," said John Alam, MD, Chief Executive Officer of CervoMed.

CervoMed Reports Third Quarter 2023 Financial Results and Business Highlights

With incorporation of key learnings, Phase 2b has >95% (approaching 100%) statistical power  to meet its primary endpoint: change in Clinical Dementia Rating Sum-of-Boxes (CDR-SB) vs. placebo  New data included in the presentation show that in patients without Alzheimer's-related co-pathology, neflamapimod treatment demonstrates significant reduction vs.

CervoMed Announces Oral Presentation at CTAD 2023 Highlighting Learnings from Phase 2a Which Optimized the Design of the Phase 2b Clinical Study of Neflamapimod in Dementia with Lewy Bodies

Final publication in Neurology® of Phase 2a Results Stratified by Plasma Phosphorylated Tau Status at Baseline Strengthens the Case for Progressing Neflamapimod as a Disease-Modifying Treatment for Dementia with Lewy Bodies Research Highlight Article in Molecular Neurodegeneration Comments That Through Acting on Cholinergic Degeneration Neflamapimod Has Potential to have Disease-modifying Effects in Both Dementia with Lewy Bodies and Alzheimer's Disease BOSTON , Oct. 24, 2023 /PRNewswire/ -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for degenerative diseases of the brain, today announced the publication of the following two articles that support advancing neflamapimod as a disease-modifying treatment for Dementia with Lewy Bodies (DLB) and Alzheimer's Disease (AD): Alam JJ, Maruff P, Doctrow S, Chu H-M, Conway J, Gomperts SN, Teunissen C. Association of plasma phosphorylated tau with the response to neflamapimod treatment in patients with dementia with Lewy bodies.

CervoMed Announces Publications in Major Peer-Reviewed Journals That Inform on Potential of Neflamapimod as a Disease-Modifying Therapy for the Major Dementias

Oral neflamapimod has the potential to reverse synaptic dysfunction, improve neuron health and slow or prevent disease progression, which would make it the first disease-modifying treatment in DLB Phase 2b RewinD-LB study underway; completion of enrollment planned in 1H 2024, and topline primary efficacy results in expected in 2H 2024 BOSTON , Oct. 18, 2023 /PRNewswire/ -- CervoMed Inc. (NASDAQ: CRVO), a clinical-stage company focused on developing treatments for degenerative diseases of the brain, today announced it will present deeper insights highlighting the neflamapimod clinical development program, including findings in phase2a that led to the final Phase 2b study design for the treatment of patients with dementia with Lewy bodies (DLB), in an oral presentation at the 16th Clinical Trials in Alzheimer's Disease (CTAD) conference, being held October 24-27, 2023, in Boston, Massachusetts. "We are pleased to have the opportunity to comprehensively present the findings in phase 2a and discuss the analyses that went into optimizing the Phase 2b study design for the treatment of patients with DLB at the upcoming CTAD conference," said John Alam, MD, Chief Executive Officer of CervoMed.

CervoMed Announces Oral Presentation at CTAD 2023 Highlighting Phase 2b Neflamapimod Program for the Treatment of Patients with Dementia with Lewy Bodies

BOSTON , Oct. 5, 2023 /PRNewswire/ -- CervoMed Inc. (NASDAQ: CRVO), a clinical-stage company focused on developing treatments for degenerative diseases of the brain, today announced it will participate in the 2023 Roth Healthcare Opportunities Conference on Thursday, October 12, 2023 in New York. Members of the Company's senior management team will be presenting and hosting 1x1 meetings at the conference.

CervoMed to Present at the 2023 Roth Healthcare Opportunities Conference

BOSTON , Sept. 5, 2023 /PRNewswire/ -- CervoMed Inc. (NASDAQ: CRVO), a clinical-stage company focused on developing treatments for degenerative diseases of the brain, today announced that the Company's senior management team will present at the H.C.

CervoMed to Present at H.C. Wainwright 25th Annual Global Investment Conference

Diffusion Pharmaceuticals

Shares of CervoMed to commence trading on Nasdaq under new ticker symbol "CRVO" on August 17, 2023 CervoMed will be focused on advancing oral stress kinase inhibitor neflamapimod for the treatment of dementia with Lewy bodies and other degenerative diseases of the brain CervoMed has a cash runway through Phase 2b clinical data which is expected during 2H 2024 BOSTON , Aug. 16, 2023 /PRNewswire/ -- CervoMed Inc. (formerly known as Diffusion Pharmaceuticals Inc.) (NASDAQ: CRVO), now a clinical-stage company focused on developing treatments for degenerative diseases of the brain, today announced the closing of its previously announced merger with EIP Pharma Inc. The combined company will operate under the name CervoMed Inc., and its shares will commence trading on a 1-for-1.5 reverse split adjusted basis on August 17, 2023, on the Nasdaq Capital Market under the ticker symbol "CRVO". CervoMed's focus will be on advancing its lead drug candidate neflamapimod, an oral stress kinase inhibitor, which is currently being developed for the treatment of dementia with Lewy bodies (DLB) and other degenerative diseases of the brain.

CervoMed Announces Completion of Merger with EIP Pharma

News for CervoMed Inc Stock (CRVO)